Profile data is unavailable for this security.
About the company
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
- Revenue in SEK (TTM)0.00
- Net income in SEK-76.25m
- Incorporated1999
- Employees11.00
- LocationAscelia Pharma ABHyllie Boulevard 34MALMO 215 32SwedenSWE
- Phone+46 462863760
- Websitehttps://www.ascelia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xbrane Biopharma AB | 209.08m | -72.86m | 206.09m | 26.00 | -- | 0.3511 | -- | 0.9858 | -5.16 | 8.99 | 14.57 | 28.49 | 0.2713 | 0.2899 | 5.00 | 3,216,539.00 | -9.46 | -37.48 | -15.30 | -65.13 | 71.25 | -- | -34.85 | -233.69 | 1.71 | -1.49 | 0.00 | -- | -16.76 | -- | 17.70 | -- | 113.17 | -- |
| Dextech Medical AB | 0.00 | -4.96m | 207.04m | 1.00 | -- | 8.66 | -- | -- | -0.2684 | -0.2684 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -18.58 | -19.36 | -18.94 | -19.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.96 | -- | 40.14 | -- |
| AlzeCure Pharma AB | 0.00 | -39.20m | 217.76m | 11.00 | -- | 4.30 | -- | -- | -0.4047 | -0.4047 | 0.00 | 0.4409 | 0.00 | -- | -- | 0.00 | -71.83 | -73.70 | -88.08 | -83.65 | -- | -- | -- | -- | -- | -- | 0.053 | -- | -- | -- | 5.20 | -- | -38.94 | -- |
| Sprint Bioscience AB | 167.17m | 91.74m | 230.02m | 30.00 | 2.62 | 1.93 | 2.48 | 1.38 | 0.8333 | 0.8333 | 1.79 | 1.13 | 1.87 | -- | 18.22 | 5,572,267.00 | 102.66 | -4.00 | 142.84 | -6.12 | 92.19 | 76.93 | 54.88 | -3.84 | -- | 17.51 | -- | -- | 154.67 | 58.17 | 601.92 | -- | -- | -- |
| Xintela AB | 2.96m | -42.28m | 235.13m | 13.00 | -- | -- | -- | 79.52 | -0.0665 | -0.0665 | 0.0046 | -0.0396 | 0.3486 | -- | 6.47 | 227,461.50 | -498.42 | -194.17 | -- | -651.77 | 100.00 | -- | -1,429.86 | -6,272.93 | -- | -16.40 | -- | -- | 5,303.85 | 156.45 | 27.54 | -- | -- | -- |
| Intervacc AB | 20.09m | -80.82m | 239.59m | 15.00 | -- | 0.8715 | -- | 11.93 | -0.2773 | -0.2773 | 0.0676 | 0.8066 | 0.0834 | 2.89 | 4.88 | -- | -33.55 | -25.82 | -36.95 | -27.87 | -57.18 | -35.02 | -402.32 | -643.48 | 8.46 | -- | 0.0003 | -- | 70.42 | 33.26 | -7.02 | -- | -37.01 | -- |
| Initiator Pharma A/S | 0.00 | -16.57m | 244.19m | 2.00 | -- | 5.27 | -- | -- | -0.2752 | -0.2752 | 0.00 | 0.6766 | 0.00 | -- | -- | 0.00 | -43.00 | -67.58 | -46.15 | -73.43 | -- | -- | -- | -- | -- | -- | 0.0619 | -- | -- | -- | 53.32 | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -113.26m | 299.47m | 27.00 | -- | 0.5012 | -- | -- | -2.17 | -2.17 | 0.00 | 9.55 | 0.00 | -- | -- | 0.00 | -17.10 | -17.73 | -17.89 | -18.72 | -- | -- | -- | -34,307.19 | -- | -- | 0.0312 | -- | -- | -- | 11.79 | -- | -7.93 | -- |
| Bio-Works Technologies AB | 41.41m | -29.78m | 302.53m | 29.00 | -- | 8.24 | -- | 7.31 | -0.50 | -0.50 | 0.5878 | 0.3738 | 0.6931 | 0.9866 | 6.45 | 1,380,200.00 | -49.84 | -50.49 | -67.92 | -61.39 | 72.68 | 70.42 | -71.91 | -140.95 | 1.65 | -- | 0.00 | -- | -41.99 | 35.51 | 34.25 | -- | -48.46 | -- |
| Circio Holding ASA | 0.00 | -8.72m | 307.34m | 9.00 | 11.19 | -- | -- | -- | 0.1348 | 0.1348 | 0.00 | -0.0836 | 0.00 | -- | -- | 0.00 | -93.87 | -47.84 | -- | -58.78 | -- | -- | -- | -6,460.26 | -- | -- | -- | -- | -100.00 | -- | 150.93 | -- | 7.12 | -- |
| Zelluna ASA | 0.00 | -133.44m | 396.17m | 26.00 | -- | 4.87 | -- | -- | -7.10 | -7.10 | 0.00 | 3.27 | 0.00 | -- | -- | -- | -128.29 | -44.36 | -165.31 | -49.63 | -- | -- | -- | -- | -- | -- | 0.008 | -- | -- | -- | 30.02 | -- | -41.59 | -- |
| Ascelia Pharma AB | 0.00 | -76.25m | 408.52m | 11.00 | -- | 4.14 | -- | -- | -0.693 | -0.693 | 0.00 | 0.7777 | 0.00 | -- | -- | -- | -60.31 | -54.24 | -85.44 | -64.44 | -- | -- | -- | -- | -- | -31.70 | 0.0097 | -- | -- | -- | 4.72 | -- | -32.17 | -- |
| Oncopeptides AB | 71.23m | -249.59m | 439.56m | 75.00 | -- | -- | -- | 6.17 | -1.08 | -1.08 | 0.3062 | -0.2278 | 0.3759 | 0.3886 | 2.34 | 949,746.70 | -131.70 | -138.07 | -176.28 | -205.55 | 96.56 | 78.40 | -350.39 | -964.18 | 2.45 | -9.55 | 1.87 | -- | 124.72 | -- | 12.31 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | -58.20m | 600.63m | 13.00 | -- | 29.89 | -- | -- | -0.2417 | -0.2417 | 0.00 | 0.0726 | 0.00 | -- | -- | 0.00 | -124.50 | -81.63 | -166.61 | -107.95 | -- | -- | -- | -- | -- | -17.91 | 0.6101 | -- | -- | -- | -1,865.03 | -- | -- | -- |
| Medivir AB | 3.98m | -77.82m | 605.71m | 10.00 | -- | 2.32 | -- | 152.03 | -0.6789 | -0.6789 | 0.0348 | 0.5831 | 0.0238 | -- | 0.9374 | 398,400.00 | -46.44 | -31.75 | -69.67 | -38.14 | -- | -- | -1,953.24 | -740.12 | -- | -70.04 | 0.00 | -- | -54.36 | -16.77 | -38.06 | -- | -- | -- |
Data as of Feb 20 2026. Currency figures normalised to Ascelia Pharma AB's reporting currency: Swedish Krona SEK
7.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Sep 2024 | 4.64m | 3.66% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 3.04m | 2.40% |
| SEB Funds ABas of 30 Jan 2026 | 777.47k | 0.61% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 646.21k | 0.51% |
| Skandia Investment Management ABas of 28 Nov 2025 | 263.47k | 0.21% |
More ▼
Data from 30 Nov 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
